INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request appointment as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced that the EFZO-FIT study, a Phase 3 trial for intravenous Efzofitimod in pulmonary sarcoidosis patients, did not meet its primary endpoint [4]. - Following the announcement of the trial results, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].